Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldesleukin and Pembrolizumab in Advanced Melanoma
NCT02748564Phase 2Terminated
- Sponsor
- Rutgers University
- Start
- Mar 2017
- Primary completion
- Oct 2018
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in melanoma, sponsored by Rutgers University. Started Mar 2017; status: terminated.
02
Drugs
aldesleukin
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02748564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02748564.